Calidi Biotherapeutics, Inc. CLDI

CLDI Company Overview

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for cancer, with an emphasis on systemic and localized delivery of oncolytic virotherapies. The company operates within the biotechnology and immuno-oncology sectors and is primarily focused on developing proprietary stem cell-based platforms designed to deliver therapeutic viruses to solid tumors while helping shield those viruses from immune clearance. Its core revenue profile is currently research and development driven, as the company remains in the clinical-development stage and does not yet generate material commercial product revenue based on publicly available filings.

Calidi’s primary business lines center on its stem cell-based delivery technologies and engineered viral therapeutics, including programs designed for high-grade glioma and metastatic solid tumors. The company positions itself through a differentiated approach that combines cell therapy with virotherapy, aiming to improve tumor targeting and systemic delivery efficiency. Calidi evolved through multiple corporate and financing transactions, including a public market listing transaction involving a special purpose acquisition company structure, after which the combined entity adopted the Calidi Biotherapeutics name and began trading on Nasdaq under the ticker CLDI.